Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,743 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 13 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Tenafly, New Jersey

Conditions: Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Interventions: Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression, Hypertension, Hypercholesterolemia
Interventions: Cognitive behavioral therapy; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 55 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Obesity, Overweight
Interventions: NB, CLI, Usual Care; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Denver, Colorado • St Louis, Missouri • Cary, North Carolina + 12 more

Conditions: Head and Neck Cancer, Carotid Artery Stenosis, Cardiovascular Complication
Interventions: Carotid ultrasound, Blood draw, Survey; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Depressive Symptoms
Interventions: Exercise, Health Education; Behavioral
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation
Interventions: Metformin, Lifestyle/Risk Factor Modification; Drug · Behavioral
Lead sponsor: Mina Chung, MD; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: clarithromycin, prasterone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Typical Atrial Flutter, Risk Factors With Future Development of Atrial Flutter
Interventions: CTI ablation alone, CTI ablation and Pulmonary vein isolation (PVI); Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overweight and Obesity
Interventions: Acceptance-based Treatment (ABT), Health Education (HE) Comparison; Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 14 Years to 19 Years · Female only
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Coronary Artery Disease
Interventions: Immediate disclosure of CAD PRS results, Deferred Disclosure of CAD PRS results; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation (AF)
Interventions: discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation; Behavioral · Drug · Procedure
Lead sponsor: China National Center for Cardiovascular Diseases; Government
Eligibility: 18 Years and older
Enrollment: 3,160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions: Apixaban 2.5 MG, Placebo oral tablet; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pre-Diabetes, Weight, Body, Cardiovascular Diseases
Interventions: Placebo, Rybelsus Tablet, Jardiance 25Mg Tablet, Metformin, Actos; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: alemtuzumab, graft-versus-tumor induction therapy, rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 40 Years to 72 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sleep
Interventions: Average American Diet (AAD), Mediterranean Diet; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Coronary Syndrome, Chest Pain
Interventions: OU - Cardiac MRI, OU - Conventional Care Testing; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Aortic Aneurysm, Abdominal
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cardiovascular Disease Risk Factors
Interventions: Education/Behavior Modification; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atherosclerosis, Diabetes
Interventions: Mindfulness-based stress reduction, Nutrition Enhancement; Behavioral
Lead sponsor: Montana State University; Other
Eligibility: 25 Years to 55 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Cardiovascular Diseases
Interventions: Clinician Nudge, Patient Nudge; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 75 Years
Enrollment: 4,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiovascular Risk Factors
Interventions: Alternative Snack Comparator, Raisins; Other
Lead sponsor: Louisville Metabolic and Atherosclerosis Research Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
Interventions: Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score; Drug · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Biological CVD Risk Factors in Older Depressed Patients

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Carotid Ultrasound to Identify Head and Neck Cancer Survivors With High Cardiovascular Risk After Radiation Therapy

Exploring the Effects of Strength Training on Depressive Symptoms and Cardiovascular Risk in Black Men

Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

Pulmonary Vein Isolation To Reduce Future Risk Of Atrial Fibrillation In Patients Undergoing Typical Flutter

An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents

Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

Prevention of Progression of Prediabetes, Obesity and CV Risk

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Evaluation of Diet and Sleep in Vascular Health: A Pilot Study

Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain

Inflammation and Risk Prediction in Patients With Abdominal Aortic Aneurysm

Reducing CVD Risk in African Americans Faith Communities

Strategies for Inflammation and Cardiovascular Disease (CVD) Prevention

Nudges for Statin Prescribing in Primary Care

Study of Raisins Versus Alternative Snacks on Cardiovascular Risk Factors In Generally Healthy Subjects

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies